44941
柠檬酸三铁（III） 一水合物
18-20% Fe basis (T)
别名:
柠檬酸铁 一水合物
质量水平
表单
solid
浓度
18-20% Fe (T)
痕量阴离子
chloride (Cl-): ≤500 mg/kg
痕量阳离子
Ca: ≤100 mg/kg
Cd: ≤50 mg/kg
Co: ≤50 mg/kg
Cu: ≤50 mg/kg
K: ≤500 mg/kg
Na: ≤200 mg/kg
Ni: ≤100 mg/kg
Pb: ≤50 mg/kg
Zn: ≤50 mg/kg
官能团
hydroxyl
SMILES字符串
OC12CC(=O)O[Fe](OC(=O)C1)OC2=O
InChI
1S/C6H8O7.Fe/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3
InChI key
NPFOYSMITVOQOS-UHFFFAOYSA-K
正在寻找类似产品? 访问 产品对比指南
应用
柠檬酸三钠一水合物铁 (III) 可用作在制备灌注溶液期间使用的其中一种组合物的铁源。
警示用语：
Warning
危险声明
危险分类
Eye Irrit. 2
储存分类代码
13 - Non Combustible Solids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
A E Gómez-Ayala et al.
Laboratory animals, 32(1), 72-79 (1998-03-03)
The effects of iron deficiency on the absorption of different dietary sources of iron were studied, together with the interactions between iron, calcium, phosphorus, magnesium, copper and zinc in the jejunum-ileum of control and iron-deficient rats. In this study, three
Keitaro Yokoyama et al.
American journal of nephrology, 36(5), 478-487 (2012-11-14)
JTT-751 (ferric citrate hydrate) is a novel oral, iron-based phosphate binder being developed for the treatment of hyperphosphatemia among chronic kidney disease patients who are on dialysis. This study investigated the dose-response and safety of JTT-751 among Japanese hemodialysis patients.
Keiji Nishida et al.
PLoS biology, 10(2), e1001269-e1001269 (2012-03-06)
Most organisms are simply diamagnetic, while magnetotactic bacteria and migratory animals are among organisms that exploit magnetism. Biogenic magnetization not only is of fundamental interest, but also has industrial potential. However, the key factor(s) that enable biogenic magnetization in coordination
Guus A M Kortman et al.
PloS one, 7(1), e29968-e29968 (2012-01-25)
Recent trials have questioned the safety of untargeted oral iron supplementation in developing regions. Excess of luminal iron could select for enteric pathogens at the expense of beneficial commensals in the human gut microflora, thereby increasing the incidence of infectious
Jamie P Dwyer et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 61(5), 759-766 (2013-02-02)
Most dialysis patients require phosphate binders to control hyperphosphatemia. Ferric citrate has been tested in phase 2 trials as a phosphate binder. This trial was designed as a dose-response and efficacy trial. Prospective, phase 3, multicenter, open-label, randomized clinical trial.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持